Compugen rises on $6 mln milestone payment from AstraZeneca

Compugen

04/10/2021 21:35

** U.S.-listed shares of drug discovery co  CGEN.O  closed
up 1.3% at $6.05, after having climbed as much as 4.7% earlier
in the session
    ** CGEN becomes entitled to receive $6 million from
AstraZeneca as patient dosing in early-stage study for Astra's
lung cancer drug begins  urn:newsml:reuters.com:*:nPnbpcX9Ta 
    ** Astra's lung cancer drug AZD2936, is derived from COM902,
Compugen's anti-TIGIT antibody, an experimental therapy which
limits the tumor's ability to evade a person's immune system 
    ** COM902 is a type of monospecific antibody, which means it
is meant to target one type of cell or tissue 
    ** CGEN granted Astrazeneca exclusive rights to use its
monospecific anti-TIGIT antibodies for developing bi-specific
and multi-specific antibody products which target more than one
cell or tissue in 2018 
    ** Up to Friday's close, U.S.-listed shares of CGEN down
~49% while AstraZeneca up ~21% YTD

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))